Triple negative breast cancer: new therapeutic approaches and BRCA status
Treatment of triple negative breast cancer (TNBC) is a clinically challenging problem due to intriguing clinical and pathologic features of TNBC and natural or induced resistance to existing therapies. However, a great understanding of features of TNBC particularly associated with BRCA mutations has...
Gespeichert in:
| Veröffentlicht in: | APMIS : acta pathologica, microbiologica et immunologica Scandinavica microbiologica et immunologica Scandinavica, 2018-05, Vol.126 (5), p.371-379 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 379 |
|---|---|
| container_issue | 5 |
| container_start_page | 371 |
| container_title | APMIS : acta pathologica, microbiologica et immunologica Scandinavica |
| container_volume | 126 |
| creator | Guney Eskiler, Gamze Cecener, Gulsah Egeli, Unal Tunca, Berrin |
| description | Treatment of triple negative breast cancer (TNBC) is a clinically challenging problem due to intriguing clinical and pathologic features of TNBC and natural or induced resistance to existing therapies. However, a great understanding of features of TNBC particularly associated with BRCA mutations has led to the development of different therapeutic approaches. Besides, identification of TNBC subtypes contribute to investigation of the underlying molecular differences and development of new strategies for the treatment of TNBC patients. In this review, we discussed the definition and characteristic properties of TNBC. We summarized an up‐to‐date description of the reported clinical trials of novel targeted strategies especially PARP inhibitors (PARPi) due to novel and highly potent for the treatment of TNBC. Additionally, we reviewed published studies which investigated the prevalence and types of BRCA1/2 mutation in breast cancer patients to assess and draw attention of association of BRCA status with TNBC. Consequently, the definition subtype of TNBC has important predictive value for the development of new therapeutic agents in the treatment of TNBC. Additionally, the incidence and types of mutations in BRCA‐related pathways may be affected by ethnic origin and contribute to the risk of developing TNBC. |
| doi_str_mv | 10.1111/apm.12836 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2031418988</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2030559991</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4546-61cc5edf109280402caa42b18ac5ad06ca260ba275b18a792eb4f832083f5e4b3</originalsourceid><addsrcrecordid>eNp10E1Lw0AQBuBFFFs_Dv4BCXjRQ9rZzWaT9VaLHwVFkXoOk-3ERtI07iYW_71bWz0IzmVgeHgZXsZOOAy4nyE2iwEXaaR2WJ8rgBCkinZZHzREoVSS99iBc28AHqlkn_WEVlolPOmzydSWTUVBTa_Ylh8U5JbQtYHB2pC99PdV0M7JYkNdW5oAm8Yu0czJBVjPgqvn8ShwLbadO2J7BVaOjrf7kL3cXE_Hd-H94-1kPLoPjYylChU3JqZZwUGLFCQIgyhFzlM0Mc5AGRQKchRJvL4lWlAuizQSkEZFTDKPDtn5Jtc_8t6Ra7NF6QxVFda07FwmIOKSpzpNPT37Q9-Wna39d2sFcay15l5dbJSxS-csFVljywXaz4xDtu438_1m3_16e7pN7PIFzX7lT6EeDDdgVVb0-X9SNnp62ER-AcxWgrQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2030559991</pqid></control><display><type>article</type><title>Triple negative breast cancer: new therapeutic approaches and BRCA status</title><source>Wiley Journals</source><creator>Guney Eskiler, Gamze ; Cecener, Gulsah ; Egeli, Unal ; Tunca, Berrin</creator><creatorcontrib>Guney Eskiler, Gamze ; Cecener, Gulsah ; Egeli, Unal ; Tunca, Berrin</creatorcontrib><description>Treatment of triple negative breast cancer (TNBC) is a clinically challenging problem due to intriguing clinical and pathologic features of TNBC and natural or induced resistance to existing therapies. However, a great understanding of features of TNBC particularly associated with BRCA mutations has led to the development of different therapeutic approaches. Besides, identification of TNBC subtypes contribute to investigation of the underlying molecular differences and development of new strategies for the treatment of TNBC patients. In this review, we discussed the definition and characteristic properties of TNBC. We summarized an up‐to‐date description of the reported clinical trials of novel targeted strategies especially PARP inhibitors (PARPi) due to novel and highly potent for the treatment of TNBC. Additionally, we reviewed published studies which investigated the prevalence and types of BRCA1/2 mutation in breast cancer patients to assess and draw attention of association of BRCA status with TNBC. Consequently, the definition subtype of TNBC has important predictive value for the development of new therapeutic agents in the treatment of TNBC. Additionally, the incidence and types of mutations in BRCA‐related pathways may be affected by ethnic origin and contribute to the risk of developing TNBC.</description><identifier>ISSN: 0903-4641</identifier><identifier>EISSN: 1600-0463</identifier><identifier>DOI: 10.1111/apm.12836</identifier><identifier>PMID: 29696717</identifier><language>eng</language><publisher>Denmark: Wiley Subscription Services, Inc</publisher><subject>BRCA1 protein ; BRCA1/2 ; Breast cancer ; Cancer ; Chemical compounds ; Clinical trials ; Medical research ; Mutation ; PARP inhibitors ; Patients ; Pharmacology ; Poly(ADP-ribose) polymerase ; Reagents ; synthetic lethality ; therapeutic agents ; Triple negative breast cancer</subject><ispartof>APMIS : acta pathologica, microbiologica et immunologica Scandinavica, 2018-05, Vol.126 (5), p.371-379</ispartof><rights>2018 APMIS. Published by John Wiley & Sons Ltd</rights><rights>2018 APMIS. Published by John Wiley & Sons Ltd.</rights><rights>Copyright © 2018 APMIS Published by John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4546-61cc5edf109280402caa42b18ac5ad06ca260ba275b18a792eb4f832083f5e4b3</citedby><cites>FETCH-LOGICAL-c4546-61cc5edf109280402caa42b18ac5ad06ca260ba275b18a792eb4f832083f5e4b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapm.12836$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapm.12836$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29696717$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guney Eskiler, Gamze</creatorcontrib><creatorcontrib>Cecener, Gulsah</creatorcontrib><creatorcontrib>Egeli, Unal</creatorcontrib><creatorcontrib>Tunca, Berrin</creatorcontrib><title>Triple negative breast cancer: new therapeutic approaches and BRCA status</title><title>APMIS : acta pathologica, microbiologica et immunologica Scandinavica</title><addtitle>APMIS</addtitle><description>Treatment of triple negative breast cancer (TNBC) is a clinically challenging problem due to intriguing clinical and pathologic features of TNBC and natural or induced resistance to existing therapies. However, a great understanding of features of TNBC particularly associated with BRCA mutations has led to the development of different therapeutic approaches. Besides, identification of TNBC subtypes contribute to investigation of the underlying molecular differences and development of new strategies for the treatment of TNBC patients. In this review, we discussed the definition and characteristic properties of TNBC. We summarized an up‐to‐date description of the reported clinical trials of novel targeted strategies especially PARP inhibitors (PARPi) due to novel and highly potent for the treatment of TNBC. Additionally, we reviewed published studies which investigated the prevalence and types of BRCA1/2 mutation in breast cancer patients to assess and draw attention of association of BRCA status with TNBC. Consequently, the definition subtype of TNBC has important predictive value for the development of new therapeutic agents in the treatment of TNBC. Additionally, the incidence and types of mutations in BRCA‐related pathways may be affected by ethnic origin and contribute to the risk of developing TNBC.</description><subject>BRCA1 protein</subject><subject>BRCA1/2</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Chemical compounds</subject><subject>Clinical trials</subject><subject>Medical research</subject><subject>Mutation</subject><subject>PARP inhibitors</subject><subject>Patients</subject><subject>Pharmacology</subject><subject>Poly(ADP-ribose) polymerase</subject><subject>Reagents</subject><subject>synthetic lethality</subject><subject>therapeutic agents</subject><subject>Triple negative breast cancer</subject><issn>0903-4641</issn><issn>1600-0463</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp10E1Lw0AQBuBFFFs_Dv4BCXjRQ9rZzWaT9VaLHwVFkXoOk-3ERtI07iYW_71bWz0IzmVgeHgZXsZOOAy4nyE2iwEXaaR2WJ8rgBCkinZZHzREoVSS99iBc28AHqlkn_WEVlolPOmzydSWTUVBTa_Ylh8U5JbQtYHB2pC99PdV0M7JYkNdW5oAm8Yu0czJBVjPgqvn8ShwLbadO2J7BVaOjrf7kL3cXE_Hd-H94-1kPLoPjYylChU3JqZZwUGLFCQIgyhFzlM0Mc5AGRQKchRJvL4lWlAuizQSkEZFTDKPDtn5Jtc_8t6Ra7NF6QxVFda07FwmIOKSpzpNPT37Q9-Wna39d2sFcay15l5dbJSxS-csFVljywXaz4xDtu438_1m3_16e7pN7PIFzX7lT6EeDDdgVVb0-X9SNnp62ER-AcxWgrQ</recordid><startdate>201805</startdate><enddate>201805</enddate><creator>Guney Eskiler, Gamze</creator><creator>Cecener, Gulsah</creator><creator>Egeli, Unal</creator><creator>Tunca, Berrin</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>7T7</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201805</creationdate><title>Triple negative breast cancer: new therapeutic approaches and BRCA status</title><author>Guney Eskiler, Gamze ; Cecener, Gulsah ; Egeli, Unal ; Tunca, Berrin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4546-61cc5edf109280402caa42b18ac5ad06ca260ba275b18a792eb4f832083f5e4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>BRCA1 protein</topic><topic>BRCA1/2</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Chemical compounds</topic><topic>Clinical trials</topic><topic>Medical research</topic><topic>Mutation</topic><topic>PARP inhibitors</topic><topic>Patients</topic><topic>Pharmacology</topic><topic>Poly(ADP-ribose) polymerase</topic><topic>Reagents</topic><topic>synthetic lethality</topic><topic>therapeutic agents</topic><topic>Triple negative breast cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guney Eskiler, Gamze</creatorcontrib><creatorcontrib>Cecener, Gulsah</creatorcontrib><creatorcontrib>Egeli, Unal</creatorcontrib><creatorcontrib>Tunca, Berrin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>APMIS : acta pathologica, microbiologica et immunologica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guney Eskiler, Gamze</au><au>Cecener, Gulsah</au><au>Egeli, Unal</au><au>Tunca, Berrin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Triple negative breast cancer: new therapeutic approaches and BRCA status</atitle><jtitle>APMIS : acta pathologica, microbiologica et immunologica Scandinavica</jtitle><addtitle>APMIS</addtitle><date>2018-05</date><risdate>2018</risdate><volume>126</volume><issue>5</issue><spage>371</spage><epage>379</epage><pages>371-379</pages><issn>0903-4641</issn><eissn>1600-0463</eissn><abstract>Treatment of triple negative breast cancer (TNBC) is a clinically challenging problem due to intriguing clinical and pathologic features of TNBC and natural or induced resistance to existing therapies. However, a great understanding of features of TNBC particularly associated with BRCA mutations has led to the development of different therapeutic approaches. Besides, identification of TNBC subtypes contribute to investigation of the underlying molecular differences and development of new strategies for the treatment of TNBC patients. In this review, we discussed the definition and characteristic properties of TNBC. We summarized an up‐to‐date description of the reported clinical trials of novel targeted strategies especially PARP inhibitors (PARPi) due to novel and highly potent for the treatment of TNBC. Additionally, we reviewed published studies which investigated the prevalence and types of BRCA1/2 mutation in breast cancer patients to assess and draw attention of association of BRCA status with TNBC. Consequently, the definition subtype of TNBC has important predictive value for the development of new therapeutic agents in the treatment of TNBC. Additionally, the incidence and types of mutations in BRCA‐related pathways may be affected by ethnic origin and contribute to the risk of developing TNBC.</abstract><cop>Denmark</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29696717</pmid><doi>10.1111/apm.12836</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0903-4641 |
| ispartof | APMIS : acta pathologica, microbiologica et immunologica Scandinavica, 2018-05, Vol.126 (5), p.371-379 |
| issn | 0903-4641 1600-0463 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2031418988 |
| source | Wiley Journals |
| subjects | BRCA1 protein BRCA1/2 Breast cancer Cancer Chemical compounds Clinical trials Medical research Mutation PARP inhibitors Patients Pharmacology Poly(ADP-ribose) polymerase Reagents synthetic lethality therapeutic agents Triple negative breast cancer |
| title | Triple negative breast cancer: new therapeutic approaches and BRCA status |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T14%3A42%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Triple%20negative%20breast%20cancer:%20new%20therapeutic%20approaches%20and%20BRCA%20status&rft.jtitle=APMIS%20:%20acta%20pathologica,%20microbiologica%20et%20immunologica%20Scandinavica&rft.au=Guney%20Eskiler,%20Gamze&rft.date=2018-05&rft.volume=126&rft.issue=5&rft.spage=371&rft.epage=379&rft.pages=371-379&rft.issn=0903-4641&rft.eissn=1600-0463&rft_id=info:doi/10.1111/apm.12836&rft_dat=%3Cproquest_cross%3E2030559991%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2030559991&rft_id=info:pmid/29696717&rfr_iscdi=true |